TW202100551A - Ｔｓｇ－６抗體及其用途 - Google Patents

Ｔｓｇ－６抗體及其用途 Download PDF

Info

Publication number
TW202100551A
TW202100551A TW109108016A TW109108016A TW202100551A TW 202100551 A TW202100551 A TW 202100551A TW 109108016 A TW109108016 A TW 109108016A TW 109108016 A TW109108016 A TW 109108016A TW 202100551 A TW202100551 A TW 202100551A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
tsg
amino acid
individual
Prior art date
Application number
TW109108016A
Other languages
English (en)
Chinese (zh)
Inventor
理查 布羅克
賈貴林 梅森
馬克 布雷
Original Assignee
大學健康網絡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大學健康網絡 filed Critical 大學健康網絡
Publication of TW202100551A publication Critical patent/TW202100551A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW109108016A 2019-03-12 2020-03-11 Ｔｓｇ－６抗體及其用途 TW202100551A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817152P 2019-03-12 2019-03-12
US62/817,152 2019-03-12

Publications (1)

Publication Number Publication Date
TW202100551A true TW202100551A (zh) 2021-01-01

Family

ID=72427149

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109108016A TW202100551A (zh) 2019-03-12 2020-03-11 Ｔｓｇ－６抗體及其用途

Country Status (14)

Country Link
US (1) US20220153834A1 (https=)
EP (1) EP3938389A4 (https=)
JP (1) JP2022522815A (https=)
KR (1) KR20210138674A (https=)
CN (1) CN113748130A (https=)
AU (1) AU2020234533A1 (https=)
BR (1) BR112021017810A2 (https=)
CA (1) CA3129302A1 (https=)
EA (1) EA202192488A1 (https=)
IL (1) IL286216A (https=)
MX (1) MX2021010766A (https=)
SG (1) SG11202109708TA (https=)
TW (1) TW202100551A (https=)
WO (1) WO2020181376A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192829A2 (en) * 2022-03-28 2023-10-05 University Of Florida Research Foundation, Incorporated Alpha-1 antitrypsin z- and m-specific binding proteins
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
KR102582500B1 (ko) 2022-10-27 2023-09-26 서울대학교산학협력단 Tnfaip6 -조작된 종양 세포 및 이의 이용
WO2024102759A1 (en) * 2022-11-07 2024-05-16 Board Of Regents, The University Of Texas System Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica

Also Published As

Publication number Publication date
CA3129302A1 (en) 2020-09-17
JP2022522815A (ja) 2022-04-20
AU2020234533A1 (en) 2021-09-16
MX2021010766A (es) 2021-12-10
SG11202109708TA (en) 2021-10-28
US20220153834A1 (en) 2022-05-19
CN113748130A (zh) 2021-12-03
WO2020181376A1 (en) 2020-09-17
IL286216A (en) 2021-10-31
EP3938389A4 (en) 2022-11-09
BR112021017810A2 (pt) 2021-11-23
EA202192488A1 (ru) 2022-02-08
EP3938389A1 (en) 2022-01-19
KR20210138674A (ko) 2021-11-19

Similar Documents

Publication Publication Date Title
US11384146B2 (en) BTLA-binding antibodies for modulating immune response and treating disease
TW202100551A (zh) Ｔｓｇ－６抗體及其用途
US12404327B2 (en) LILRB3-binding molecules and uses therefor
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
US12286476B2 (en) FCMR-binding molecules and uses thereof
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения